Research article · 12 Jun 2025
Conference abstractPublished 2017
Vascular-targeted TNFα and IFNγ inhibited orthotopic colorectal tumor growth
Chinese University of Hong Kong, Hong Kong, China Southwest Medical University, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ) were originally identified to show potent anti-tumor activity and immunomodulatory capability. Unfortunately, several clinical studies of relevant cancer therapy did not observe significant response in maximum tolerated dose whether given alone or in combination. This unfavorable outcome was largely due to the nonspecific action and widespread systemic toxicity found in the body. We used a phage display technology to identify a tumor vasculature homing peptide (TCP-1) which targeted mainly at the vasculature of colorectal tumors but not normal blood vessels in animals and humans. With this discovery, we biologically conjugated the two immunomodulators individually with TCP-1 in order to provide a targeted therapy and perhaps also lessen the systemic side effects incurred by TNFα and IFNγ when given alone or combined treatment. In this study, we determined the antitumor effect and systemic toxicity of the new conjugates TCP-1/TNFα and TCP-1/IFNγ either given alone or in combination in an orthotopic colorectal tumor model in mice. Targeted delivery of TNFα or IFNγ by TCP-1 peptide exhibited better antitumor activity than unconjugated moieties by inducing more tumor apoptosis and also enhancing antitumor immunity shown by increased infiltration of T lymphocytes inside the tumor. TCP-1/TNFα also normalized tumor blood vessels and increased anti-cancer drug concentration in the tumor. Interestingly combined therapy with TCP-1/TNFα and TCP-1/IFNγ synergistically suppressed tumor growth and alleviated systemic toxicities associated with untargeted therapy. This combination of drug treatment induced massive apoptosis/secondary necrosis in tumors. Taken together, our data demonstrates TCP-1 is an efficient drug carrier for targeted therapy of colorectal cancer (CRC). TCP-1/TNFα combined with TCP-1/IFNγ is a promising combination of immunotherapy for CRC.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmaceutics & Drug Delivery Research.
Research article · 20 Feb 2025
Sustained Drug Delivery in Pharmaceutical Dosage Forms for Novel Approaches of Formulation Design
Research article · 23 Jan 2025
Cutting Out Counterfeits: How Blockchain Can Revolutionize Drug Traceability?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutics & Drug Delivery Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Chi Hin Cho”
- BylineArticles whose byline prints “Jing Shen”
